Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 140Esophageal Neoplasms 71Pancreatic Neoplasms 42Esophageal Squamous Cell Carcinoma 26Carcinoma, Non-Small-Cell Lung 24Adenocarcinoma Of Esophagus 23Breast Neoplasms 18Neoplasms 15Neoplasm Metastasis 15Colorectal Neoplasms 15Prostatic Neoplasms 11Ovarian Neoplasms 9Melanoma 9Squamous Cell Carcinoma of Head and Neck 8Lung Neoplasms 8Adenocarcinoma 8Sarcoma 7Colonic Neoplasms 7Biliary Tract Neoplasms 7Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Gastrointestinal Neoplasms 5Gallbladder Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Rectal Neoplasms 4Head and Neck Neoplasms 4

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1Oxaliplatin 1HMPL-013 1Docetaxel 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastric Cancer Adenocarcinoma Metastatic × Docetaxel × Gastrointestinal × Clear all
NCT00517829 2016-11-28

Docetaxel+Oxali+/-Cetux Met Gastric/GEJ

US Oncology Research

Phase 2 Completed
150 enrolled 12 charts
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡